Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can antibodies and vaccine work together? new study investigates

NCT ID NCT04852978

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether giving Regeneron's antibody treatment (casirivimab+imdevimab) along with the Moderna COVID-19 vaccine changes how well the vaccine works. About 295 healthy adults took part. Researchers measured immune responses and checked safety to see if the timing between the antibody shot and the vaccine matters.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

295 people

The number who actually took part.

Started

Apr 2021

Finished

Nov 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: 1. Healthy or has chronic medical condition(s) that are stable and well-controlled in the opinion of the investigator and that are not likely to require significant medical intervention through the end of study 2. Willing and able to comply with study visits and study-related procedures, including compliance with site precautionary requirements related to SARS-CoV-2 infection and transmission Key Exclusion Criteria: 1. Positive RT-PCR test result for SARS-CoV-2 infection at screening or baseline 2. Positive serology test result for anti-SARS-CoV-2 antibodies at screening or baseline 3. COVID-19 diagnosis, positive SARS-CoV-2 infection, or positive SARS-CoV-2 serology at any time prior to screening 4. Previously received an investigational, authorized, or approved coronavirus vaccine (eg, SARS-CoV-2 vaccine, MERS-CoV vaccine) 5. Currently enrolled in, or has plans to enroll in, any interventional study to prevent or treat COVID-19 6. Received investigational or approved passive antibodies for SARS-CoV-2 infection prophylaxis ad defined in the protocol 7. Received intravenous immunoglobulin (IVIG) or blood products in the last 3 months 8. Any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the subject by study participation 9. History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric or neurological disease, as assessed by the investigator, that may confound the results of the study or pose an additional risk to the subject by study participation 10. Medically attended acute illness or hospitalization (ie, \>24 hours) for any reason within 30 days prior to screening 11. Clinical history of myocarditis and/or pericarditis Note: Other protocol-defined Inclusion/ Exclusion Criteria apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic stable illness are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Regeneron Research Site

    Little Rock, Arkansas, 72211, United States

  • Regeneron Research Site

    Rogers, Arkansas, 72758, United States

  • Regeneron Research Site

    Hialeah, Florida, 33012, United States

  • Regeneron Research Site

    Miami, Florida, 33186, United States

  • Regeneron Research Site

    Orlando, Florida, 32789, United States

  • Regeneron Research Site

    Dayton, Ohio, 45417, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.